Cover Image

Navigating Drug–Drug Interactions in Clinical Drug Development: A Tutorial

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Jesmin Lohy Das, Antoinette (Toni) Ajavon‐Hartmann, Virginia (Ginny) D. Schmith
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Clinical and Translational Science
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tutorial Drug–Drug Interactions
by: Edward M. Sellers
Published: (2025)

Clinical Evaluation of Drug–Drug Interactions With Aficamten
by: Neha Maharao, et al.
Published: (2026)

Clinical Significance of Drug–Drug Interaction Studies During Therapeutic Peptide Drug Development: Follow‐Up Investigation of Therapeutic Peptides Approved Between 2021 and 2024
by: Carolina Säll, et al.
Published: (2025)

Development and Validation of an Approach to Assessing Clinical Relevance of Potential Drug–Drug Interactions Inducing Rare but Serious Adverse Events
by: Menghuan Song, et al.
Published: (2025)

Prevalence of OATP1B‐Mediated Drug–Drug Interactions in an Academic Medical Center
by: Mathilde Bories, et al.
Published: (2025)

Assessment of Food Effect and pH‐Dependent Drug–Drug Interactions of Fruquintinib in Healthy Subjects
by: Martha Gonzalez, et al.
Published: (2025)

A Tutorial and Use Case Example of the eXtreme Gradient Boosting (XGBoost) Artificial Intelligence Algorithm for Drug Development Applications
by: Matthew Wiens, et al.
Published: (2025)

Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants
by: Jack Chang, et al.
Published: (2025)

Impact of Dose‐Escalation Design on the Safety and Development of Anticancer Drugs in Clinical Trials
by: Atsushi Nonami, et al.
Published: (2025)

Unlocking the Mysteries of Rare Disease Drug Development: A Beginner's Guide for Clinical Pharmacologists
by: Mariam A. Ahmed, et al.
Published: (2025)

Population Pharmacokinetic Model Assessment of the Effects of Body Weight on Risk of Drug–Drug Interactions After Posaconazole Discontinuation
by: Rebecca E. Wrishko, et al.
Published: (2026)

Use of Biomarkers in Drug Development for Regulatory Purposes
by: Robert N. Schuck, et al.
Published: (2025)

Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug–Drug Interaction Study in Patients With Non‐Hodgkin Lymphoma
by: Masaya Tachibana, et al.
Published: (2025)

Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates
by: Paulien Ravenstijn, et al.
Published: (2026)

Modulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug–Placebo Differences
by: Martin Coenen, et al.
Published: (2025)

Exploratory Evaluation of Solanidine as an Endogenous Marker for CYP2D6 ‐Mediated Drug–Drug–Gene Interactions of Venlafaxine in Koreans
by: Sungyeun Bae, et al.
Published: (2026)

A Modeling Investigation of the CYP1A Drug Interactions of Riluzole
by: Paul Malik, et al.
Published: (2025)

Optimizing Oligonucleotide Therapeutics: A Model‐Informed Drug Development Perspective
by: Ye Yuan, et al.
Published: (2026)

Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority
by: Mark J. Ratain, et al.
Published: (2025)

Retrospective Analysis of Master Protocols in Tumor‐Agnostic Drug Development: Evaluation of Application to Single‐Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs
by: Keiko Yamamoto, et al.
Published: (2025)

Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants
by: Alison Luckey, et al.
Published: (2026)

From Precision to Personalized: Catalyzing AI ‐Enabled Innovation in Drug Development
by: Adarsh Subbaswamy, et al.
Published: (2026)

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics‐Based Biomarkers
by: Bhagwat Prasad
Published: (2026)

Promising Drugs Require Proper Testing
by: Jean‐Jacques Parienti
Published: (2026)

Predictive Analysis for First Submission of Generic Drug Application for Orphan Drug Products Using Random Survival Forest
by: Robert Hopefl, et al.
Published: (2025)

When Selectivity Increases Uncertainty: Context‐Dependent Pharmacology in Antibody Drug Development
by: Xiaozhi Liao, et al.
Published: (2026)

Surrogate Endpoints in Pivotal Clinical Trials for Drug Approval in Japan Compared to the United States
by: Yuko Yamamoto, et al.
Published: (2025)

Integrating Model‐Informed Drug Development With AI: A Synergistic Approach to Accelerating Pharmaceutical Innovation
by: Karthik Raman, et al.
Published: (2025)

Clinical Pharmaceutical Care in Nursing Home Residents as a Cornerstone for Drug‐Related Problems Identification
by: Milada Halačová, et al.
Published: (2025)

Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model
by: Zimin Zhang, et al.
Published: (2025)

The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications
by: Virginia D. Schmith, et al.
Published: (2026)

Cross‐Reactive NSAID Hypersensitivity: Clinical Findings From Aspirin Provocation and Alternative Drug Challenge Testing
by: Young‐Il Koh, et al.
Published: (2025)

Empirical Drug Dosage Validates Pharmacogenomic Associations in All of Us
by: Jan Matthias, et al.
Published: (2025)

Predicting the Pharmacokinetics of T‐Cell Engagers as a Function of Target‐Mediated Drug Disposition
by: Mark Penney, et al.
Published: (2025)

Absolute oral bioavailability of milvexian spray‐dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approach
by: Praneeth Jarugula, et al.
Published: (2024)

From Models to Medicines: A Narrative History and Regulatory Perspective on the Translational Impact of Model‐Informed Drug Development ( MIDD )
by: Issam Zineh
Published: (2026)

A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes
by: Ilia Rattsev, et al.
Published: (2026)

High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment
by: Eric J. Lenze, et al.
Published: (2025)

Informing Dose for Pediatric Rare Diseases—A Survey of Recent Orphan Drugs Approvals
by: Elimika Pfuma Fletcher, et al.
Published: (2026)

Drug Interaction PBPK Modeling: Review of the Literature Exposes the Need for Increased Verification of Model Inputs and Outputs as Part of Credibility Assessment
by: David Rodrigues, et al.
Published: (2025)